Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.

A legfontosabb adatok

Ki végzi
University Hospital, Basel, Switzerland
Hol
Ausztria, Hollandia, Horvátország, Lengyelország, Németország, Olaszország, Svájc és Svédország11 helyszín, 8 országbanVálassz országot a helyszínekhez
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
150 fő, tervezett
Kezdés
2025. júl. 15.
Várható befejezés
2030. jan.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Engineered cartilage graft (N-TEC)
  • Autologous Matrix Induced Chondrogenesis (AMIC)
  • Patellofemoral Arthroplasty (PFA)
A regiszteradat frissítve
2026. március 24.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with painful arthritis behind the kneecap (patellofemoral osteoarthritis). It compares a lab-grown cartilage graft made from the patient's own nose cells with standard knee surgery.

Életkor
18 to 70 years
Nem
All sexes
A betegség stádiuma
Painful patellofemoral osteoarthritis grade 1-4 (Iwano Classification), with cartilage damage grade 3-4 (ICRS) of the kneecap, the thigh-bone groove or both. KOOS-5 knee score below 75. Knee must bend at least 125° and lose no more than 5° of straightening.
Korábbi kezelés
Exercise programs and first-line medicines such as topical NSAIDs did not help enough. No knee surgery on the target knee in the last 12 months, except a diagnostic arthroscopy with cleaning and rinsing. No joint injections into the knee in the last 3 months.
Biomarker vagy leletérték
Blood values: women need haemoglobin of at least 120g/l, men at least 140g/l. Platelets at least 150G/l and INR<1.3 for all.

A részvétel fő kizáró okai

  • Arthritis or pain in the main inner knee joint (Kellgren and Lawrence grade > 2), or a symptomatic meniscus tear
  • Body mass index (BMI) >35 kg/m2, rheumatoid or infectious arthritis, or loose knee ligaments
  • HIV/AIDS, acute syphilis, or active hepatitis B or C
  • Pregnant, breastfeeding or planning pregnancy within 24 months after surgery
  • Weak immune system or immune-suppressing medicines, higher bleeding risk, or cannot have an MRI

A regiszter feltételei, szó szerint

Mind a 36 feltétel megnézéseKevesebb

Ki vehet részt

  • Patient age is ≥18 and ≤ 70 years at time of screening
  • Symptomatic PFOA grade 1-4 according to Iwano Classification
  • Chondropathy Grade 3-4 according to ICRS classification of the patella, trochlea femoris or both
  • Baseline score of <75 on the KOOS-5 subjective knee evaluation
  • Free range of motion of the affected knee joint or ≤ 5° of extension loss and minimum 125° flexion
  • Patient is willing and able to give written informed consent to participate in the study and to comply with all study requirements, including attending all follow-up visits and assessments and to complete postoperative rehabilitation regimen
  • Minimum values for women: Haemoglobin 120g/l, Platelets 150G/l, INR<1.3
  • Minimum values for men: Haemoglobin 140g/l, Platelets 150G/l, INR<1.3
  • Patients have failed to demonstrate adequate response to non-pharmacological interventions (e.g. structured land-based exercise programs) and pharmacological first-line treatment such as topical NSAIDs

Ki nem vehet részt

  • Prior surgical treatment of the target knee within 12 months (Note: prior diagnostic arthroscopy with debridement and lavage are acceptable within 12 months)
  • Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee
  • Patient had any intra-articular injections into the affected knee within the last 3 months before baseline visit
  • Patient is pregnant, breast feeding or anticipates becoming pregnant within 24 months after surgery
  • Patient is currently participating or has participated in any other clinical study within 3 months prior to the screening visit
  • Patients who will likely benefit from conservative therapy, such as physiotherapy, medical training therapy and pain medication
  • Patients with increased anesthesiological and surgical risks (e.g. known or predicted difficult airway, myocardial infarction <60 days prior to surgery)
  • Radiologically apparent degenerative joint disease of the tibiofemoral joint as determined by X-ray (Kellgren and Lawrence grade > 2) or MRI or pain in the tibiofemoral joint as assessed by clinical examination
  • Patient has a known immunological suppressive disorder or is taking systemic immunosuppressives
  • The patient has a HIV/AIDS infection. (regulatory requirement)
  • The patient has an acute Treponema pallidum (syphilis) infection. (regulatory requirement)
  • The patient has an active hepatitis B or C infection with verified antigens. Patients with a cured hepatitis B or C infection and/or verified antibodies are not excluded. (regulatory requirement)
  • Patient has known current or recent history of illicit drug or alcohol abuse or dependence defined as the continued use of alcohol or drugs despite the development of social, legal or health problems
  • Patient has any other condition, which, in the opinion of the investigator, would make the patient unsuitable for the study
  • Known allergies for porcine collagen (scaffold), penicillin or streptomycin (manufacturing)
  • Nail-patella syndrome
  • Patients with increased bleeding risk (e.g. coagulopathies)
  • Patients on anticoagulants whose anticoagulant therapy cannot be interrupted as appropriate to the given agent(s) and underlying condition
  • Patients with any active infections
  • Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol or in a dependency or employment with the sponsor
  • Patient is unwilling, unable or lacking the capacity to provide informed consent
  • Patient is unable to undergo magnetic resonance imaging (MRI)
  • Patient has excessive varus or valgus deformity (>5°), unless corrected during implantation
  • Patient has a symptomatic meniscus lesion (or removal exceeding ½), as indicated by clinical examination (joint line tenderness and McMurray test positive) and MRI
  • Patient has a body mass index (BMI) >35 kg/m2
  • Patient has chronic rheumatoid arthritis, and/or infectious arthritis
  • Instability of anterior, posterior and/or collateral ligaments

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 70 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

8 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

ENCANTO is a randomized, controlled, multi-center phase II clinical trial for the treatment of patellofemoral osteoarthritis (PFOA) with an Advanced Therapy Medicinal Product (ATMP), nasal chondrocyte-based tissue engineered cartilage (N-TEC) implantation in comparison with current standard of care depending on the stage of osteoarthritis. The goal of this phase II trial is to evaluate the efficacy of N-TEC treatment in comparison to an active comparator Autologous Matrix Induced Chondrogenesis (AMIC) for early stage PFOA or patellofemoral arthroplasty (PFA) for late stage PFOA.

A teljes eredeti leírásKevesebb

The N-TEC engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.

A vizsgálat 4 csoportja

  • Engineered cartilage graft (N-TEC)-Iwano grade 1-2A vizsgált kezelés

    N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.

    Kezelés: Engineered cartilage graft (N-TEC)

  • Autologous Matrix Induced Chondrogenesis-Iwano grade 1-2Már használt kezelés, összehasonlításként

    AMIC® Chondro-Gide® combines microfracturing (MFx) with the use of Chondro-Gide®, which covers and protects both the super clot resulting from MFx and the repair tissue.

    Kezelés: Autologous Matrix Induced Chondrogenesis (AMIC)

  • Engineered cartilage graft (N-TEC)-Iwano grade 3-4A vizsgált kezelés

    N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The IMP is implanted in the knee at the patellofemoral joint.

    Kezelés: Engineered cartilage graft (N-TEC)

  • Patellofemoral Arthroplasty (PFA)-Iwano grade 3-4Már használt kezelés, összehasonlításként

    Patellofemoral Joint Prosthesis

    Kezelés: Patellofemoral Arthroplasty (PFA)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Randomized, Controlled, Multi-center Phase II Clinical Trial for the Treatment of Patellofemoral Osteoarthritis With Nasal Chondrocyte-based Tissue Engineered Cartilage Implantation vs Current Standard of Care
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06576583: ki vehet részt
A regiszteradat frissítve
2026. március 24.